Market Cap
$2.2B
AUPH
Aurinia Pharmaceuticals Inc.
$15.77 ▼ -1.13%
Prev close $15.95Market cap$2.2B
ConsensusBuy
12-mo target$17.86 (+13.2%)
▲ Bullish
Analyst conviction 8/10
High Impact Filing (8/10)19 New Institutional Positions16 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on AUPH right now — valuation, ownership and activity at a glance.
Cap Size
Mid Cap
Analyst Consensus
Strong Buy (77%)
Inst. Holders
50 funds
Inst. Value
$878.5M
Inst. Activity
19 buys / 16 sells
Insider Activity
$25.1M buy / $546.4K sell
Insider Net $
$24.6M
SEC Reports
4
Price chart 30d -3.2%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 10, 2026 Insider
Robertson Stephen P. sold 11,939 shares
Chief Legal Officer @ $15.95 ($190.4K)
Aug 25, 2026 Event
LUPKYNIS
WARNING: MALIGNANCIES AND SERIOUS INFECTIONS Increased risk for developing malignancies and serious
Aug 21, 2026 Insider
Robertson Stephen P. sold 20,975 shares
Chief Legal Officer @ $16.97 ($355.9K)
Aug 19, 2026 short_volume
Aug 6, 2026 SEC Short Volume: AUPH — 60.8% short (0.5M / 0.8M)
Short: 463,787 | Exempt: 0 | TRF Vol: 762,581 | Short Ratio: 60.8% | Off-exchange volume (dark pool
Aurinia Pharmaceuticals reported Q2 2026 revenue of $83.2M (+19% YoY) and diluted EPS of $0.28 (+75% YoY), both exceedin
8-K — Impact 6/10
Jun 30, 2026 Inst.
GOLDMAN SACHS GROUP INC — DOUBLED
5,619,401 shares ($95.4M)
Jun 30, 2026 Inst.
Jun 8, 2026 SEC JUPITER ASSET MANAGEMENT LTD — ADD
1,094,475 shares ($18.6M)
Aurinia CEO Kevin Tang made a conviction buy of ~552K shares (~$8.4M in open-market purchases) over three days, with bul
INSIDER-BUY — Impact 6/10
Analyst ratings buy % +11.6%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
77% rate it Buy or better · 13 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Aug 7, 2026 | RBC Capital | MAINTAIN | Sector Perform | 55% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 3 | 7 | 3 | 0 | 0 | 77% | |
| Aug 1, 2026 | 3 | 6 | 4 | 0 | 0 | 69% | |
| Jul 1, 2026 | 3 | 6 | 4 | 0 | 0 | 69% | |
| Jun 1, 2026 | 3 | 6 | 4 | 0 | 0 | 69% | |
| May 1, 2026 | 3 | 6 | 4 | 0 | 0 | 69% | |
| Apr 1, 2026 | 3 | 6 | 4 | 0 | 0 | 69% | |
| Mar 1, 2026 | 3 | 6 | 4 | 0 | 0 | 69% | |
| Feb 1, 2026 | 3 | 6 | 4 | 0 | 0 | 69% |
Price targets
Where 7 covering analysts think AUPH trades over the next 12 months.
$17.86 +13.2% upside Buy
Current$15.77 Low$16.00 Median$17.00 High$21.00 7 analysts
$16.00$21.00
Analyst rating None as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
4 SEC filing reports analyzed · 3 bullish, 0 bearish, 0 mixed, 1 neutral · avg impact 6.3/10.
BULLISH8-K6/10
Aurinia Pharmaceuticals reported Q2 2026 revenue of $83.2M (+19% YoY) and diluted EPS of $0.28 (+75%
Aug 6, 2026
BULLISHINSIDER-BUY6/10
Aurinia CEO Kevin Tang made a conviction buy of ~552K shares (~$8.4M in open-market purchases) over
Jun 8, 2026
NEUTRAL8-K5/10
Aurinia Pharmaceuticals completed its acquisition of Kezar Life Sciences via a tender offer and merg
May 11, 2026
BULLISH8-K8/10
Aurinia Pharmaceuticals reported strong financial results for 2025, with total revenue up 20% year-o
Feb 26, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Aug 25, 2026
FDA
LUPKYNIS
WARNING: MALIGNANCIES AND SERIOUS INFECTIONS Increased risk for developing malignancies and serious infections with LUPKYNIS or other immunosuppressan
Aug 19, 2026
short_volume
Short Volume: AUPH — 60.8% short (0.5M / 0.8M)
Short: 463,787 | Exempt: 0 | TRF Vol: 762,581 | Short Ratio: 60.8% | Off-exchange volume (dark pool + OTC)
Aug 7, 2026
ftd
FTD: AUPH — 179,974 shares ($2.9M) failed to deliver
Settlement: 20260807, Price: $16.13, FTD Value: $2,902,980.62, AURINIA PHARMACEUTICALS INC OR
Aug 6, 2026
short_volume
Short Volume: AUPH — 55.7% short (0.4M / 0.7M)
Short: 395,759 | Exempt: 85,976 | TRF Vol: 710,303 | Short Ratio: 55.7% | Off-exchange volume (dark pool + OTC)
Aug 3, 2026
short_volume
Short Volume: AUPH — 58.7% short (0.3M / 0.6M)
Short: 328,612 | Exempt: 6,725 | TRF Vol: 559,854 | Short Ratio: 58.7% | Off-exchange volume (dark pool + OTC)
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $0.22 | $0.21–$0.25 | -4.3% | -9.3% | 1↑ 2↓ | $0.1B | 5 |
| Next Q | $0.20 | $0.16–$0.25 | -86.9% | -16.7% | 0↑ 2↓ | $0.1B | 5 |
| Current FY | $0.94 | $0.90–$1.01 | -54.4% | -1.7% | 1↑ 2↓ | $0.3B | 5 |
| Next FY | $1.07 | $0.51–$1.64 | 13.0% | -4.3% | 1↑ 3↓ | $0.4B | 6 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $0.220 | — |
| 7d ago | $0.238 | -0.018 |
| 30d ago | $0.242 | -0.022 |
| 60d ago | $0.242 | -0.022 |
| 90d ago | $0.242 | -0.022 |
Institutional ownership
Which big funds own AUPH (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $878.5M total value (51,762,262 shares) as of 2026-Q2. Top holders: BlackRock,, GOLDMAN, TWO. Net buying activity: 19 institutions added/increased vs 16 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| BlackRock, Inc. | 8,193,085 | $139.0M | 15.8% | — |
| GOLDMAN SACHS GROUP INC | 5,619,401 | $95.4M | 10.9% | DOUBLED +292.0% |
| TWO SIGMA INVESTMENTS, LP | 3,467,514 | $58.8M | 6.7% | — |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 3,264,062 | $55.4M | 6.3% | — |
| STATE STREET CORP | 2,589,615 | $43.9M | 5.0% | — |
| MORGAN STANLEY | 2,308,244 | $39.2M | 4.5% | — |
| MARSHALL WACE, LLP | 2,044,007 | $34.7M | 3.9% | — |
| GEODE CAPITAL MANAGEMENT, LLC | 1,701,152 | $28.9M | 3.3% | — |
| RENAISSANCE TECHNOLOGIES LLC | 1,548,035 | $26.3M | 3.0% | — |
| D. E. Shaw & Co., Inc. | 1,408,456 | $23.9M | 2.7% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| GOLDMAN SACHS GROUP INC | DOUBLED | 1,433,508 | 5,619,401 | +292.0% | $95.4M |
| JUPITER ASSET MANAGEMENT LTD | ADD | 803,419 | 1,094,475 | +36.2% | $18.6M |
| Allianz Asset Management GmbH | NEW | — | 841,731 | — | $14.3M |
| O'SHAUGHNESSY ASSET MANAGEMENT, LLC | ADD | 414,019 | 567,492 | +37.1% | $9.6M |
| Qube Research & Technologies Ltd | TRIM | 930,631 | 479,970 | -48.4% | $8.1M |
| BNP PARIBAS FINANCIAL MARKETS | TRIM | 748,765 | 437,037 | -41.6% | $7.4M |
| WELLS FARGO & COMPANY/MN | ADD | 275,154 | 411,825 | +49.7% | $7.0M |
| VOLORIDGE INVESTMENT MANAGEMENT, LLC | TRIM | 528,172 | 362,416 | -31.4% | $6.2M |
| MILLENNIUM MANAGEMENT LLC | DOUBLED | 117,169 | 244,302 | +108.5% | $4.1M |
| BANK OF AMERICA CORP /DE/ | TRIM | 371,781 | 225,082 | -39.5% | $3.8M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
12 insiders, 43 transactions. Net $24.6M — $25.1M bought, $546.4K sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 10, 2026 | Robertson Stephen P. | Chief Legal Officer | SELL | 11,939 | $15.95 | $190.4K |
| Aug 21, 2026 | Robertson Stephen P. | Chief Legal Officer | SELL | 20,975 | $16.97 | $355.9K |
| Jun 4, 2026 | Johnson Craig A | Director | AWARD | 23,931 | — | — |
| Jun 4, 2026 | Nova Tina Susan | Director | AWARD | 23,931 | — | — |
| Jun 4, 2026 | Bailey Jeffrey Allen | Director | AWARD | 23,931 | — | — |
| Jun 4, 2026 | Goetz Kathleen | Director | AWARD | 23,931 | — | — |
| Jun 2, 2026 | TANG KEVIN | Chief Executive Officer | J | 10,000 | $1.65 | $16.5K |
| Jun 2, 2026 | TANG KEVIN | Chief Executive Officer | BUY | 206,005 | $15.28 | $3.1M |
| Jun 1, 2026 | TANG KEVIN | Chief Executive Officer | BUY | 99 | $15.34 | $1.5K |
| Jun 1, 2026 | TANG KEVIN | Chief Executive Officer | BUY | 343,521 | $15.28 | $5.2M |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for AUPH.
Shares short
8,576,505
Settlement Sep 15, 2026
Change vs prior
-4.5%
Semi-monthly cycle
Days to cover
11.1
At avg daily volume
Of shares outstanding
≈6.5%
Estimate — not % of float
All AUPH filing & press-release reports (4)
- 8-K reportAug 6, 2026
- INSIDER-BUY reportJun 8, 2026
- 8-K reportMay 11, 2026
- 8-K reportFeb 26, 2026